Antibody Validation for Western blot: By the User, for the User

Lakshmi Pillai-Kastoori1**, Sam Heaton2**, Steve D. Shiflett1, Annabelle C. Roberts2, Alejandra Solache2 and Amy R. Schutz-Geschwender1

From: 1 LI-COR Biosciences, 4647 Superior Street, Lincoln, NE 68504, USA; 2 Abcam plc, Discovery Drive, Cambridge Biomedical Campus, Cambridge, CB2 0AX, UK

Running title: Antibody validation for Western blotting

#To whom correspondence should be addressed: Dr. Lakshmi Pillai-Kastoori, LI-COR Biosciences, Lincoln, NE 68504; lakshmi.pillai@licor.com; Tel. +1(402) 467-0679

* Joint first authorship

Keywords: antibody, immunochemistry, antigen, Western blot, protein domain, validation, immunoblot, methodology, reproducibility, specificity

ABSTRACT

Well-characterized antibody reagents play a key role in the reproducibility of research findings, and inconsistent antibody performance leads to variability in Western blotting and other immunoassays. The current lack of clear, accepted standards for antibody validation and reporting of experimental details contributes to this problem. Because the performance of primary antibodies is strongly influenced by assay context, recommendations for validation and usage are unique to each type of immunoassay. Practical strategies are proposed for the validation of primary antibody specificity, selectivity, and reproducibility using Western blot analysis. The antibody should produce reproducible results within and between Western blot experiments, and the observed effect confirmed with a complementary or orthogonal method. Routine implementation of standardized antibody validation and reporting in immunoassays such as Western blotting may promote improved reproducibility across the global life sciences community.
INTRODUCTION

Repeated observations are essential to the scientific method. They help to confirm that experimental observations are meaningful and reflect a biological truth when combined with robust statistical analysis. Despite this, however, the reproducibility of research findings has been a growing concern (1,2). Sources of irreproducible research include incomplete reporting of experimental details, lack of reagent validation and controls, differences in analytic techniques or measurements and differences in interpretation of results (3,4).

Many of the issues above arise from a common cause: that researchers perform similar assays in many different ways. Lack of a unifying framework or set of standards is a clear barrier to reproducibility. In the life sciences, use of accepted standards can promote reproducibility by developing consensus-based methods that reduce unintentional differences between experiments, as well as improving data reporting practices in order to increase awareness of intentional differences between experiments (4-7).

Several peer-reviewed journal editors have commented on issues related to the lack of reproducible antibodies in life science research (8), and multiple initiatives are trying to look at ways in which antibodies can be standardized, including evaluation, protocols, and documentation. In 2016, the International Working Group for Antibody Validation (IWGAV) proposed guidelines for improving standards for antibody use and validation (5). More recently, the National Institutes of Health (NIH) released new guidelines for grant submission that requires investigators to describe how they will “ensure the identity and validity of key biological resources”, including antibodies (NOT-OD-18-228). The international community has also come up with a proposal called Minimum Information About a Protein Affinity Reagent (MIAPAR), which aims to establish a stronger connection between antibody producers and users. MIAPAR-compliant data includes information such as the production/purification process, experimental evidence, updated protocols, and other relevant details (7,9).

In addition improving the standardization of antibodies, antibody performance is another common source of variability in Western blotting. The Western blot process relies on two key properties of primary antibodies: specificity, an antibody’s ability to recognize and bind to its target antigen; and selectivity, an antibody’s preference to bind its target antigen in the presence of a heterogeneous mixture of competing sample proteins. Well-characterized antibodies that consistently perform as expected are therefore essential for robust, reproducible research. Unfortunately, antibody performance can vary considerably between suppliers and even batches.

Antibody specificity and selectivity are highly dependent on the particular assay context and can be difficult to predict. Recommendations for antibody validation are different for each type of immunoassay, and an antibody that performs well in one assay, such as a Western blot, might not be suitable for another assay (10-13). Even within one type of assay, small differences in assay conditions (intentional or unintentional) can affect antibody performance (8,14-17). To ensure reproducible results, it is important to evaluate antibodies within the intended assays and experimental contexts. Assay-specific validation should confirm that the primary antibody is specific for its target antigen and that it selectively binds its target antigen.
in the presence of other antigens. Here, antibody validation recommendations for Western blot are discussed and outlined with relevant examples from the IWGAV guidelines.

Defining antibody validation for Western blotting

"Validation" is the experimental proof and documentation that a particular antibody is suitable for the intended assay or purpose (11). In a Western blot context, proper validation is therefore proof that an antibody is specific to its intended target when bound to a membrane and can selectively bind to that target within a complex heterogeneous sample, such as cell or tissue lysates. Proposed methods of antibody validation for Western blot include genetic controls, independent-epitope strategies, testing of multiple cell lines, proteomic approaches, additional evaluation of phospho-specific antibodies, and orthogonal or complementary methods (5,18). Of these strategies, KO validation of antibodies is seen as the accepted “gold” standard for Western blot and is increasingly being used by antibody vendors during the development and batch testing of primary antibody products. However, a single validation strategy is not sufficient and a combination of strategies should be used for assay-specific validation of an antibody (18,19), including those carried out by the antibody supplier/distributor. Figure 1 demonstrates several practical approaches to verify the specificity, selectivity, and reproducibility of antibodies used in Western blot analysis.

Characterization by the supplier/distributor

When choosing an antibody for Western blot experiments, suppliers/distributors should provide comprehensive information relating to the type of antibody and its performance in multiple applications. A datasheet for each antibody should include the source (polyclonal, monoclonal, or recombinant) and whether it has been purified, the type of immunogen used, lysate(s) tested, application-specific conditions (dilutions, sample concentrations, lot/batch information, etc.), and methods used to confirm antibody specificity and selectivity. Ideally, it should also provide validation and specificity data from multiple cell lines or tissues, with appropriate positive and negative controls. Selecting an antibody that has been validated for Western blot analysis is highly recommended. If chosen suppliers/distributors provide validation data and assay conditions for Western blotting, this is an indication that they recognize the importance of thorough antibody characterization. Online search engines such as those listed in Table 1 offer advanced search and filtering options to identify commercial antibodies that may have user-submitted validation data and scientists should be encouraged to share this type of data with the scientific community through appropriate portals.

Evaluation by the user: trust, but verify

There is no guarantee that a given antibody will specifically detect and bind the target-of-interest, either in samples or in an experimental context (20), even if it has been raised against this target antigen. If the antibody has been validated for Western blot either by the supplier/distributor or elsewhere, it should still also be confirmed by the user to suitable for the intended experiment and assay context (18). Certain assay conditions, such as blocking reagents, can have a surprisingly large impact on antibody performance (Figure 2). Each unique sample context is also relevant, given
that samples from diverse sources and systems may contain different cross-reactive epitopes and produce different patterns of nonspecific binding.

**Batch Variation**

A significant source of irreproducibility is variation between batches of antibodies. Vendors and researchers producing antibodies are highly encouraged to perform validation testing on every batch produced. Using recombinant antibodies eliminates the need for continued animal or hybridoma usage and reduces batch variation, especially when compared to polyclonal antibodies. Recombinant antibody production is carried out via a synthetic DNA expression vector introduced into a suitable expression system (21) that removes traditional reliance on hybridoma cells. This technique reliably produces high titers of homogenous antibody while avoiding hybridoma instability and/or “genetic drift” that can compromise performance. The sequence for an antibody variable domain can be accessed from a validated monoclonal-producing hybridoma, or from synthetic libraries through phage display technologies (22). Recombinant monoclonal antibodies provide the largest benefit to both manufacturers and scientists as they can be produced at scale in a short time with unlimited supply and greater consistency.

**Validating Antibody Specificity**

Detection of a single, distinct protein band of the expected molecular weight on a blot may not always indicate antibody specificity. Antibody specificity is the ability of an antibody to recognize and bind its target epitope. However, a single distinct band may represent the desired target protein, a cross-reactive sample protein, or a mixture of different proteins (see Holmseth et al. (23) for more details). By contrast, if a Western blot shows multiple bands this might not indicate non-specific binding, as additional bands may represent protein degradation, post-translational modification (PTM) cleavage, splice variants of the target protein, or other proteins that also contain the target epitope. Therefore, it is important to confirm that the antibody recognizes the target protein in the intended assay, and understand the significance of any additional bands (5,24) (Figure 3).

**Controls**

Appropriate positive and negative controls are essential for all Western blot experiments. Controls aid the recognition of all potential sources of error and if required, the need for intervention before results and interpretations are compromised (25,26).

**Positive controls**

Positive controls provide information about the success of immunoblotting protocols. A positive result in a positive control lane indicates that the immunodetection protocol worked and lends validity to the other assay results. On the other hand, a negative result for a positive control suggests that at least one step in a protocol did not work correctly or that the antibody used is responsible for the result.

Using lysate from cell lines known to express a specific target protein can provide a suitable positive control. With this type of control, a positive result indicates the protocol worked, and that any negative results are potentially due to low expression or absence of the target in the tested samples. “Overexpression” lysates can be appropriate positive controls for routine blots but should not be used to validate antibody selectivity or evaluate off-
Different cell lines and tissues will likely have varying protein compositions, so it is advised to test an antibody on multiple cell or tissue types to build up a protein expression profile. RNA and protein expression profiles can also be accessed online, making it easy to compare experimental data with expected cell line-/tissue-specific results (Table 2). It is critical to remember that biologically, it is common for RNA levels to not match protein levels so direct comparisons between mRNA and protein levels may not be applicable (27,28).

Negative controls

Negative controls provide information about antibody binding specificity and can indicate problems such as off-target binding and false positive results. Knockout (KO) and knockdown (KD) cell lines, lysates or tissues can be very good negative controls but have some limitations (see Limitations below). If KO or KD samples are not available, the next recommended step is to consult one of the expression databases listed in Table 2. Protein expression scores based on antibody staining are indicative of the selectivity and specificity of the antibody used. Both parameters should be supported with published data from the literature where possible.

Genetic verification

Removal of target protein expression within a given cell or tissue type generated by a gene knockout (KO) technique is the accepted standard for validation of specificity by testing against a true negative sample. Signals are compared between positive control and knockout (negative control) samples, with the absence of the expected banding on a Western blot in the KO sample strongly indicating primary antibody specificity (Figure 4B). Reversely, a positive signal from validated KO lysates can be taken as evidence of antibody off-target binding and consequently, poor specificity (Figure 4A). An alternative to knockout validation is using transient gene knockdown (KD). Both KO and KD have advantages and disadvantages, discussed below. Because genetic verification can be performed in the relevant experimental context, it is an excellent tool for assay-specific validation of antibody performance. The increasing prevalence of CRISPR-Cas9-based KO techniques and resources has allowed many labs to genetically verify the specificity of commercially-available antibodies to key pharmacological targets. Studies using KO tests failed to confirm the specificity of commercial antibodies for G-protein-coupled receptors and α1-adrenergic receptors etc. (75-78).

CRISPR-Cas9

A popular option for gene KO is the clustered regularly interspaced short palindromic repeat/CRISPR associated protein-9 (CRISPR-Cas9)-based strategy (29-33). CRISPR-Cas9 introduces site-specific double-stranded DNA breaks at the target genetic location. The host cell DNA repair machinery may then disrupt the genetic locus through a frameshift mutation. These KO samples provide valuable tools for antibody validation, as a loss of signal during testing confirms that the tested antibody has bound to its intended target. The commercial availability of CRISPR constructs makes this technology accessible to most labs.

RNA interference

KD by RNA interference (RNAi) is a useful alternative to KO for genetic verification.
Small (or short) interfering RNAs (siRNAs) can induce transient silencing of the target gene and suppress target protein expression (34). On a Western blot, siRNA KD can significantly decrease – or even completely suppress – the intensity of the target protein band, compared to the untreated sample. The Antibodypedia Validation Initiative recommends at least 50% KD of the target protein to serve as a valid negative control, compared to appropriate wild-type controls (ref: www.antibodypedia.com (35)).

**Limitations**

- Validation may not be suitable for target proteins that are essential for cell survival.
- KD and KO may trigger compensatory changes in the physiology of the cell, leading to results that are not physiologically relevant (14).
- Signal from an incomplete knockdown of target protein expression may mask off-target binding.
- While gene knockout results in complete and long-lived reduction in target protein abundance, the effects of gene knockdown are transient and dependent on consistent and sustained siRNA expression over time.

The extent of KD or KO must be validated experimentally before the sample is used as a control for antibody validation. This validation should include both genomic and proteomic approaches. Some gene editing methods may not completely eliminate the targeted protein and/or result in a truncated protein, and a corresponding antibody may also detect the truncated forms of its target protein (16,36-38).

In addition to using appropriate controls, often-overlooked aspects of the Western blotting process such as pre-adsorption (“blocking”) can also have significant effects on the outcome and consistency of experiments.

**Pre-adsorption with blocking peptides**

Although pre-adsorption tests are not recommended for antibody validation, some researchers do use pre-adsorption controls in IHC and other immunoassays (8,14,17-19,39,40). In this test, the antibody is pre-incubated with a molar excess of the immunogen used to generate it (the “blocking peptide”). If antibody binding is specific to its immunizing peptide, pre-adsorption will substantially decrease the intensity of protein staining. This method has several limitations, however. The blocking peptide may inhibit off-target binding of the antibody to antigens with the same epitope and produce an “illusion of specificity” (23) or the antibody may recognize related epitopes present in the sample. Although this test may prove that an antibody is specific, it cannot validate that it is selective (18,41). Pre-adsorption controls may be most useful when using crude sera (23). As a monoclonal or affinity-purified polyclonal antibody has already been selected for its ability to bind the target antigen, pre-adsorption provides little additional information. Overall, routine use of pre-adsorption controls for antibody validation is discouraged (16,18,41,42).

**Orthogonal and independent approaches.**

Orthogonal validation requires transcriptomics or antibody-independent proteomics to validate the differential protein expression seen with antibody assays. The transcriptomic analysis incorporates mRNA-based assays (43,44) and gene expression assays such as luciferase reporters (45,46) to
determine if sample gene expression correlates with antibody binding patterns. While these strategies can be used where endogenous protein expression is not well characterized, they can be compromised by a lack of correlation between RNA expression and protein abundance (86), along with minimal variation in sample protein expression (47). Importantly, transcriptomic analysis will struggle to conclusively validate antibodies to post-translational modifications. This is because post-translational processing is often determined by cell signaling and protein interactions rather than gene expression. Proteomic orthogonal validation includes targeted proteomics and mass spectrometry (48,49). A high-throughput ‘capture Western blot’ that utilizes biotinylated protein samples and microsphere-based barcoded antibody assays (PAGE-MAP) has also recently been developed to aid validation using the IWGAV pillars(50). While these are valuable tools for confirming antibody specificity through an analysis of protein levels between samples, they have issues differentiating co-migrating proteins of a similar molecular weight (71). However, these tools are most effective when combined with antibody assays, such as immunoprecipitation mass spectrometry (IP-MS) that can identify cross-reactive antigens through peptide mass fingerprinting (51).

Other independent validation approaches may include ELISA, immunohistochemistry, immunocytochemistry, tissue microarrays, and peptide arrays or reverse-phase protein arrays (13,52). As discussed previously, an antibody used for Western blotting is not necessarily suitable for use in other applications. An independent antibody-based assay may, therefore, use a different antibody to the one undergoing Western blot validation. Confirmation of Western blot results via independent assays may provide biological verification or validation of an observed experimental effect. They can also support biological reproducibility via replicated results and/or independent verification of an observed experimental effect or response (26,53). Importantly, findings of independent experimental approaches help to determine if a finding is biologically relevant and is potentially applicable to other samples or experimental systems. It is important to consider the state of the proteins within the independent assay and the impact this may have on antigen recognition by the antibody. Formalin-fixed, paraffin-embedded (FFPE) tissue samples in immunohistochemistry may present a radically different range of epitopes when compared with denatured and reduced protein immobilized onto a membrane. Therefore, evidence of specificity within an independent assay can support, but not substitute, evidence of specificity within Western blot experiments.

**Confirming and Improving Selectivity**

**Endogenous levels of target expression**

In a Western blot experiment, the ratio of the target to other proteins in the sample is skewed and unrelated sample proteins are typically present in considerable excess. The antibody must be able to locate and selectively bind the target antigen in a complex mixture. Target protein concentration strongly influences antibody selectivity, therefore purified or overexpressed target protein should not be used as the sole protein sample for antibody validation. Overexpression of the target alters the balance of protein abundance in assays, giving the antibody an artificial advantage (5,54,55). An overexpressed target may mask off-target binding that creates false-positive results at endogenous target expression levels. If an affinity-tagged protein is used for
validation it should be expressed at endogenous levels (5). Purified protein gives no opportunity to evaluate off-target binding but can be valuable for confirming antibody reactivity with the target. Nevertheless, endogenous samples should always be present to evaluate potential off-target binding (Figure 5) for proper demonstration of antibody specificity.

**Antibody dilution and concentration**

Antibody concentration and incubation time can affect selectivity and non-specific binding (11,56). A high-affinity primary antibody can bind and detect its antigen at a low working concentration, while a low-affinity antibody will require a higher working concentration. By contrast, higher working concentrations increase the likelihood of off-target binding and cross-reactive bands that could mask the protein of interest. The optimal concentration of the primary antibody that produces the best blot signal-to-noise ratio should be determined experimentally. A product’s recommended usage conditions can be taken as guidelines; however, they may be based on different assay conditions or reagents. A titration experiment with a series of antibody dilutions is a practical way to do this (Table 3 has guidelines on the dilution of unpurified antibodies).

For best results, it is good practice to maintain consistent experimental conditions by choosing a fixed incubation time with a consistent secondary antibody concentration and test each primary antibody dilution on the same type of sample. Secondary antibody concentration also affects the selectivity of a primary antibody. Too much secondary antibody will increase off-target binding on a blot, and too little may produce faint signals. Note that the recommended dilution range is dependent on the type of secondary antibody conjugate and detection method selected. For example, the recommended dilution for an HRP conjugate and chemiluminescent detection may not be appropriate for a fluorescent antibody conjugate.

Monoclonal antibodies have similar batch-to-batch consistency, and it may only be necessary to perform the titration once. However, especially for polyclonal antibodies, there can be differences between batches of the same antibody, and it is good practice to perform a titration for each new batch. Because antibody concentration may vary between batches and/or product suppliers, it is essential that both the 1) dilution factor and 2) antibody concentration in mass units per volume of diluent (µg/mL) are reported in publications (17). Storage and re-use (“recycling”) of diluted primary antibodies is not recommended as the inconsistent quality, titer, and stability of recycled antibodies is a potential major source of error that can negatively affect the reproducibility of results.

**Blocking buffers**

A blocking buffer should reduce the non-specific binding of antibodies to off-target sample proteins on the membrane and to the membrane itself. It should also stabilize the blotted sample proteins without disrupting their retention on the membrane surface (57-59). This enhances the specificity and selectivity of the antibody, increasing the signal-to-noise ratio for detection of the target.

Blocking buffers should not mask the interaction of the antibody with the target antigen, or display enzymatic activity or other properties that may interfere with antibody/antigen interaction or target protein detection (57). Bovine serum albumin (BSA), nonfat dry milk, and casein are commonly
used blocking buffers that differ in blocking strength and may interfere with target protein detection in some assay contexts.

Nonfat dry milk is inexpensive and widely used. It has a high blocking strength that may disguise some antigens and can also inhibit biotin-streptavidin interactions (60). Endogenous biotin and IgGs in milk can also potentially cross-react with sheep or goat secondary antibodies. Casein, an abundant protein in found in nonfat dry milk, is a phosphoprotein that may cross-react with some phospho-specific antibodies and increase background signal (56).

BSA is a popular alternative to milk-based blockers and may be more suitable for detection of antibodies labeled with biotin or alkaline phosphatase (57,59). However, some sources of BSA contain phospho-tyrosine residues that may bind anti-phosphotyrosine antibodies, and endogenous carbohydrates may interfere with detection of lectins (57,59). BSA blockers can increase non-specific banding. When used for fluorescent Western blot assays, BSA can cause increased membrane background (shown in Figure 2; (61,62). Non-mammalian blocking agents are less likely to contain cross-reactive epitopes and may produce lower background signal than mammalian reagents, which are often available from suppliers of fluorescent Western blotting platforms.

Extended blocking times and/or high concentrations of blocking agents can mask antibody/antigen interactions, reducing the signal intensity of target protein bands (56,58). Excessive blocking can cause loss of sample proteins from the surface of the membrane, particularly with nonfat dry milk. Den Hollander and Befus demonstrated nonselective elution of blotted proteins from the membrane in proportion to the amount of milk used, with progressive loss over time (63). The strength of blocking agent and length of incubation should be considered when staining for low abundance proteins.

Membrane blocking, antibody incubations, and washes often use tris-buffered saline (TBS) or phosphate-buffered saline (PBS) buffer systems. TBS buffers should be used for the detection of phosphoproteins, to avoid interference from the phosphates in PBS buffers. TBS can also be used for the detection of alkaline-phosphatase conjugated secondary antibodies (58). In some cases, a product supplier might specifically recommend PBS or TBS buffers for an antibody in order to obtain optimal results.

**Experimental replication**

At a minimum, results should be repeatable within and between Western blot experiments (18,64) and all samples should be run with replicates. A robust antibody should generate the same result regardless of the day, the user or the laboratory – with replicates (both biological and technical) of n ≥ 3 as the norm rather than the exception. Replication of results in a different laboratory adds another level of confidence. It confirms the robustness of the antibody and the experiment itself, given the multitude of small differences that may exist between the methods, equipment, and reagents used (64).

Operator habits and technique at the bench can affect results, with as much as ~80% of variation arising from “inter-operator” variability (65). Such unintentional variations such as minor differences in antibody dilution, antibody incubations, washes, and other aspects of the Western blot procedure can be a substantial source of error. Detailed reporting of experimental procedures is an effective way to reduce this type of error, with many peer-reviewed journals now encouraging this level of transparency.
Even so, it is still common for published studies to omit key details of the Western blot procedure such as the type of detection performed (enzymatic vs. fluorescence) and how the authors document results (film exposure, timing of exposure, digital imaging, etc.). Without such critical information, other researchers may be unable to reproduce the experimental results.

Even so, it is still common for published studies to omit key details of the Western blot procedure used. Such information includes what system fluorescent detection was captured on, and the associated system settings. Similarly, for enzymatic detection it is important to report whether film or camera was used and what the exposure time was. Without such critical information, other researchers may be unable to reproduce the experimental results.

Tackling the current challenges and considerations in traditional Western blotting techniques is important, as is the need to look forward to other techniques and variations on this technique that will be of significant benefit to researchers in future. Some of these techniques may improve a number of parameters that are current challenges to the traditional technique and therefore could promote greater consistency of results, including multiplexing, advances in expression tags and the detection of protein modifications.

**The future is now: Multiplex fluorescent Western blot target detection**

The future of Western blotting lies in harnessing the biological sample to the maximum capacity via multiplexed detection. While Western blotting is a staple assay of many labs, they still present several limitations. The assay can be manual, slow, time-intensive during most steps and difficult to automate at scale. Electroblotting to a membrane and subsequent antibody incubations can also lead to substantial antigen loss (50). Capillary electrophoresis and microfluidic Western blotting (66) represent two areas of innovation of the core assay concept. Microfluidic Western blotting improves on the current process by both down-scaling size and increasing multiplexing, achieving detection of 10 separate proteins on one membrane with a fraction of the sample (67,68). Capillary Western blotting through capillary gel electrophoresis (CGE) replaces the existing gel and membrane system with protein separation, immobilization and staining in a single column (69). CGE is considered to increase reproducibility of western blots, improve quantification, reduce hands-on time and improve automation potential (70). It is important to note that with the change in assay context, the behavior of antibodies also changes. Therefore direct comparison of protein expression and modification on a single membrane by multiplexing antibodies provides the best advancement in antibody validation for Western blotting. Spectrally-distinct fluorophores can be conjugated to primary antibodies or secondary detection antibodies to allow simultaneous detection on one blot. Figure 3 demonstrates how co-localization and co-migration of independent epitopes in the same target band can be evidence of antibody specificity. Here, domain-specific primary antibodies directed against the N- and C-terminus of the target are used to analyze the overlap of staining and domain-specific bands. This technique can also be used to analyze protein isoforms (20,71). This method also enables analysis of protein modifications relative to the unmodified target. Figure 6 demonstrates analysis of phosphorylation of Akt and figure 7 shows proteolytic cleavage of PARP1, with both figures analyzing the endogenous, unmodified protein within the same samples.
Relative quantification of ubiquitination, sumoylation, glycosylation and acetylation are obtainable in this system (53-56). Current methods rely on detection of primary antibodies using spectrally-distinct fluorophores, either conjugated directly to the primary antibody or through binding of secondary antibodies. Digital detection of fluorophores can also be used in combination with enzymatic detection (figures 5, 6 and 7), further increasing multiplex capabilities.

**Multiplexed detection of Expression tags**

Expression tags enable a different kind of multiple-antibody strategy. In this approach, the target protein can be modified with an affinity tag (such as His6, c-Myc, HA, or FLAG) or fluorescent protein (GFP, RFP, mCherry, etc.). The antibody under evaluation and a well-characterized immunoreagent that binds the tag are both used to examine a panel of samples on separate blots. Correlation of results between the two blots is an indicator of antibody specificity. While this approach can be taken with traditional Western blot techniques, Figure 5 demonstrates the advantages of multiplex fluorescence Western blot when performing multiple-antibody analysis. Both techniques demonstrate co-localization of primary antibody binding and detection of the epitope tag, however, multiplexing and visualization of binding on the same blot removes potential errors between membranes and assures greater accuracy of analysis. When planning to use tagged proteins, there are some potential issues to account for. An affinity tag may affect the conformation, trafficking, or function of the target protein (72-75). This risk can be minimized by placing the tag at the N- or C-terminus of the target protein. In rare instances, the junction of the target protein and expression tag may create a “neoantigen” that the antibody cannot recognize (72-74).

**Validation of Multiplex Immunoblotting**

The binding of both primary and secondary antibodies should be validated in a multiplex format to ensure that cross-reactivity does not affect the interpretation of experimental results. Primary antibodies should have been previously validated, with a well-characterized binding pattern under similar experimental conditions. It is important to run control blots with separate and combined primary antibodies in order to identify potential cross-reactivity or binding interference. Because of this, it is important to be able to discriminate between primary antibodies on a single blot. When using secondary antibodies, this can be achieved through the recognition of different antibody species or isotypes. Alternatively, primaries can be conjugated to different fluorophores or enzymes for direct detection. Detection of new cross-reactive bands may indicate that the assay requires further optimization or that a different primary antibody might be required.

Secondary antibodies should be validated across all species or isotypes present within the immunoassay. To control for secondary cross-reactivity, each primary antibody should be tested in combination with the opposite secondary antibody of mismatched specificity and checked for the presence of spurious bands. Highly cross-adsorbed secondary antibodies can prevent cross-reactive binding to other antibody species used in the assay. This type of control is particularly important in certain circumstances, for example where two protein targets co-migrate closely, or the experimental samples contain immunoglobulins that could cross-react with the secondary antibodies.
Validation of pan/phospho and pan/post-translational modification analysis

Post-translational modifications (PTMs) such as protein phosphorylation can be analyzed by multiplexing a modification-specific primary antibody with an antibody that recognizes the target protein regardless of its modification state (pan-specific antibody). Multiplexed analysis allows the monitoring of relative changes in phosphorylation levels across a group of samples, with the target protein acting as its own internal loading control. This approach eliminates the error and uncertainty introduced by stripping and re-probing of blots (76) and accounts for changes in abundance of the target protein.

The Journal of Biological Chemistry now recommends the above method for quantitative Western blot analysis of phosphorylation, stating that, “signals obtained using antibodies specific for phosphorylated epitopes should be normalized to the total protein level of the target protein” (Instructions for Authors (2018) JBC. Org[online]; http://www.jbc.org/site/misc/ifora.xhtml (Accessed March 16, 2018). However this method only compares the relative abundance of modified forms and does not indicate stoichiometry (76).

Validation of antibody specificity is crucial for pan/PTM analysis, as the modified and unmodified forms of the target are likely to co-migrate closely. Therefore, the key validation steps below should be kept in mind:

1. Perform separate Western blots with each primary antibody to characterize the banding patterns.
2. Test each primary antibody separately with the opposite, mismatched secondary antibody as described above. Cross-reactive bands could affect data analysis and interpretation if modified and unmodified forms of the target co-migrate or multiple forms are detected on the blot.
3. Verify that the PTM-directed antibody is specific for the intended modification and does not cross-react with the unmodified target. Enzymatic addition or removal (Figure 6) of the PTM is an elegant validation tool for this.
4. Evaluate any new pan- and PTM-specific antibody combination for possible binding interference. In one study, single-plex and multiplex antibody combinations were examined, however little to no interference effect was observed (77).

Reporting Western blot data in peer-reviewed publications

Antibody validation is a complex problem and is currently without completely clear or established international standards. However, each researcher can contribute to the solution – by including the full details of validation and experimental methods in manuscript submissions, providing raw validation data when requested, depositing validation results and methods in existing databases, and providing feedback to product suppliers about purchased antibodies (24,78).

Detailed disclosure of antibody-related validation details and experimental methodologies is an important first step, and some journals now require or strongly encourage this practice (79-81). Recommendations for the reporting of antibody validation for Western blot are summarized in Table 4. Detailed information for all antibodies should be included,
including the species of origin, supplier name, catalog number, clone name or number, batch or lot number, antibody name, preparation method (i.e. monoclonal, polyclonal, recombinant), type of antigen used, and research resource identification (RRID) (82) or other unique identifiers (7,82-84).

Any evidence of primary antibody validation and specificity should be reported, and if possible raw data for validation experiments should be included to facilitate peer review. When reporting validation information, include the antibody characteristics tested, validation strategy and methods, assay conditions including blocking buffers, antibody dilutions, and incubation times, positive and negative controls used, and sample information including as cell or tissue type, organism/species, lysate, purified or overexpressed protein, and growth or stimulation conditions (24,78). Adopting thorough and consistent publication practices is essential for transparency, validation, and reporting with research antibodies.

**Conclusion**

Antibodies are a major source of variation in Western blot results and subsequent analysis. Inconsistencies in the quality, validation, and reporting of research antibodies have previously been demonstrated to compromise the reproducibility of research results (3,7,85,86). In this paper, practical recommendations have been outlined that can help researchers best choose, validate, and use research antibodies in Western blot assays. We have adopted the 5 pillars of antibody validation proposed by the IWGAV(5), specifically, the enhanced strategies proposed recently for Western blotting applications (87). The data presented here demonstrates the use of a multi-pronged approach for antibody validation, including genetic knockout (Figure 4), independent antibodies (Figure 3), and recombinant expression strategy (Figure 5). Although unintended variation cannot be eliminated, it is important to verify antibody performance, especially in the relevant experimental context and assay. Emphasis has been placed on strategies for Western blot validation in Table 5.

Collectively, the reproducibility of research antibodies is a high priority in the scientific community. Although a universal framework of standards has not yet emerged, there is general agreement that rigorous validation should include, at a minimum, evaluation of antibody specificity and reproducibility (88-90). However, the requirements and recommendations for antibody validation are different for each type of immunoassay – and antibody reagents must be evaluated for the specific assay and context in which they will be used.

Having checkpoints at each stage of antibody production, sale, transport, usage, and publication of the data generated using antibodies are some of the most effective measures that can be used by the life sciences industry to counter the reproducibility crisis in Life Science and biomedical research. Suppliers/distributors, scientists, journals and funding agencies need to have a consensus and detailed processes and protocols on antibody validation. This is a very exciting time for techniques such as Western blotting with the availability and accessibility of newer technologies like recombinant antibodies, multiplex-compatible fluorophores, capillary gel electrophoresis, and microfluidic Western blotting all highlighting the importance of antibody-based protein detection assays. Antibody suppliers and publishers should also continue to refine and expand their commitment to rigorous, reproducible
science and provide corresponding quality control and validation data alongside corresponding developments in validation-enabling technologies. If antibody suppliers and consumers can work together towards this shared goal (Figure 8), it might be possible to overcome the current antibody reproducibility crisis and enter a more rigorous, productive era of antibody-based research.

Materials and Methods

Cell Culture

A431 (ECACC; 85090402), HeLa (ECACC; 93021013), LNCaP (ATCC; CRL-1740™), Jurkat (ATCC; TIB-152™), Human near-haploid cells (HAP1) (Horizon Discovery, Cambridge, UK; C631), HAP1 PARP1 knockout (Horizon Discovery; HZGHC003943c006), A549 and A549 ABCC1 knockout cells (Oxford Genetics, Oxford, UK) were cultured at 37°C in a humidified atmosphere containing 5% CO₂. A431 and HeLa cells were cultured in Minimum Essential Media (MEM) (Life Technologies; 21090022) supplemented with 10% fetal bovine serum (FBS) (Life Technologies; 10101145), 2 mM L-Glutamine (Life Technologies; 25030-024) and 1% non-essential amino acids (NEAA) (Life Technologies; 11440-050). LNCaP and Jurkat were cultured in RPMI 1640 media (Life Technologies; 22409-015) supplemented with 10% FBS and 2 mM L-Glutamine. A549 and A549 ABCC1 KO cells were cultured in Dulbecco’s Modified Essential Media (DMEM) (Life Technologies) supplemented with 5% FBS and 2% L-glutamine. Cells were cultured up to 80% confluence and pelleted before being stored at -80°C.

Cell lysis

Cells were resuspended in 150µl radioimmunoprecipitation assay (RIPA) buffer (SIGMA; R0278) supplemented with 10X Protease inhibitor cocktail (SIGMA; P2714) and 10µl phosphatase inhibitor cocktail (SIGMA; P5726) per 1x10⁷ cells and incubated on ice for 10 minutes. Lysates were sonicated for 50-second intervals until no pellet was visible and then clarified by centrifugation at 8000 rcf for 10 minutes at 4°C. The supernatant was taken and protein concentration determined by bicinchoninic acid (BCA) assay as previously described (91). Lysates were diluted in 4X SDS loading buffer (Invitrogen; NP0007) and 10% 1M Dithiothreitol (DTT) before being stored at -80°C.

Commercial Cell lysates

Isocitrate dehydrogenase (IDH1) (NM_005896) human recombinant protein (OriGene# TP310582), IDH1(NM_005896) human over-expression lysate supplied with parental HEK293T lysate (OriGene# LY401782; HEK293T LY500001; Lot #0076CF), IDH1 Knockout cell lysate (supplied with Parental HeLa control lysate) (Origene #LC810112, LC810Hela; Lot #1601), were mixed with either 2X protein loading buffer (PLB) (LICOR# 928-40004) OR 2x SDS buffer (OriGene) and denatured by boiling at 97°C for 5 minutes. The aliquots were then immediately placed on ice for 5 minutes before being spun down.

Western Blot

Lysates were loaded onto NuPAGE 4-12% 15 well Bis-Tris gels (Invitrogen; NP0323BOX), NuPAGE™ 10% Bis-Tris, 1.0 mm, 10-well protein gels (ThermoFisher Scientific; NP0301BOX), or NuPAGE 3-8% Tris Acetate gels (Invitrogen; EA03752BOX) and run at 200V for 55
minutes or 150V for 60 minutes, respectively. Gels were wet transferred using 20% methanol onto either NuPAGE Nitrocellulose 0.2µm pore sheets (Invitrogen; LC2000) or Odyssey® Nitrocellulose membranes;0.22 µM; 7 cm x 8.5 cm (P/N 926-31090). Membranes were blocked for one hour at room temperature in Odyssey Blocking Buffer (TBS) (LI-COR 927-50000) or the stated blocking solution. Primary antibodies were diluted with their respective blocking buffers (see figure legends) and incubated overnight at 4°C. Washes were performed with TBS 0.1% Tween-20 (TBS-T) before addition of secondary antibody for one hour at room temperature. Washes were performed with 1X TBST before imaging. For demonstration of equal protein loading following multi-color imaging, membranes were incubated with HRP-conjugated GAPDH primary antibody (ab9385) for 1 hour at room temperature in Odyssey Blocking Buffer (TBS). Membranes were washed with TBS-T before staining was developed using Optiblot ECL Detect kit (ab133406) and imaged on a GBOX XT-16 chemiluminescent imager with 20 minutes exposure.

Membrane Alkaline Phosphatase treatment

Following the Western blot transfer step, membranes were rinsed with deionized water before incubation with FastAP Thermosensitive Alkaline Phosphatase (ThermoFisher Scientific; EF0652), at 150U/mL in the supplied FastAP buffer, for 1 hour at 37°C. Incubated membranes were agitated every 15 minutes. Control membranes were incubated in FastAP buffer only. Membranes were rinsed twice with TBS 0.1% Tween-20 (TBS-T) before being washed for 10 minutes. Membranes were then incubated in the required blocking buffer

Antibodies

Primary antibodies used in this study were purchased from Abcam (Cambridge, UK); anti-MRP1 (ab24102), anti-alpha tubulin (ab52866), anti-MRP1 (ab233383), anti-vinculin (ab130007), anti-IDH1 (ab172964), anti-C-Myc tag (ab32), rabbit monoclonal IgG isotype control (ab172730), Mouse monoclonal IgG1 isotype control (ab18443), anti-beta catenin (ab231305 and ab35272), anti-GAPDH HRP-conjugated (ab9385), anti-PARP1 (ab32138), anti-cleaved PARP1 (ab110315), anti-AKT1 pSer473 (ab81283) and anti-AKT1 (ab108202). Antibody binding for multi-color Western blotting was detected using Goat anti-Rabbit IgG H&L (IRDye® 800CW), Goat anti-Mouse IgG H&L (IRDye® 680RD), Goat anti-Mouse IgG H&L (IRDye® 800CW) and Goat anti-Rabbit IgG H&L (IRDye® 680RD) preadsorbed secondary antibodies (LI-COR Biosciences; 926-32211, 926-68070, 926-32210, 926-68071). Chemiluminescent detection was achieved using HRP-conjugated Goat anti-Mouse IgG (H + L) (LI-COR 926-80011; Lot #C80716-02) and HRP-conjugated Goat anti-Rabbit IgG (H + L) (LI-COR 926-95000; Lot #C90214-01).

Imaging

Multi-color Western blots were imaged wet on the Odyssey® CLx imaging system using 700 nm and 800 nm channels and visualized using ImageStudio software version 5.2 (LI-COR Biosciences). HRP-conjugated GAPDH primary antibody binding was detected using a GBOX XT-16 chemiluminescent imager (Syngene). Chemiluminescent detection of IDH1, c-Myc and isotype controls was imaged with Odyssey Fc® imaging system. Adobe Photoshop Elements 5.0 and 13.0 was used to prepare image panels and annotations.
ACKNOWLEDGMENTS

The authors thank Bill Hinchen and Jon Goodding for their copy and graphical contributions to the manuscript; and Samuel S. Egel, Teresa Urlacher, Kristi Ambroz, and Jon Anderson for critical review of the manuscript.

CONFLICT OF INTEREST STATEMENT

L. Pillai-Kastoori, S.D. Shiflett and A. Schutz-Geschwender are employees of LI-COR Biosciences.

S. Heaton, A. Roberts, and A. Solache are employees of Abcam plc.
REFERENCES

1. Nature. (2016) Reality check on reproducibility. Nature 533, 437

2. Baker, M. (2016) 1,500 scientists lift the lid on reproducibility. Nature 533, 452-454

3. Lithgow, G. J., Driscoll, M., and Phillips, P. (2017) A long journey to reproducible results. Nature 548, 387-388

4. GBSI. (2013) The case for standards in Life science research. GBSI

5. Uhlen, M., Bandrowski, A., Carr, S., Edwards, A., Ellenberg, J., Lundberg, E., Rimm, D. L., Rodriguez, H., Hiltke, T., Snyder, M., and Yamamoto, T. (2016) A proposal for validation of antibodies. Nat Meth advance online publication

6. Baker, M. (2015) Antibody anarchy: A call to order. Nature 527, 545-551

7. Bourbeillon, J., Orchard, S., Benhar, I., Borrebaeck, C., de Daruvar, A., Dubel, S., Frank, R., Gibson, F., Gloriam, D., Haslam, N., Hiltker, T., Humphrey-Smith, I., Hust, M., Juncker, D., Koegl, M., Konthur, Z., Korn, B., Krobitsch, S., Muyldermans, S., Nygren, P.-A., Palcy, S., Polic, B., Rodriguez, H., Sawyer, A., Schlaphsy, M., Snyder, M., Stoevesandt, O., Taussig, M. J., Templin, M., Uhlen, M., van der Maarel, S., Wingren, C., Hermjakob, H., and Sherman, D. (2010) Minimum information about a protein affinity reagent (MIAPAR). Nat Biotech 28, 650-653

8. Saper, C. B. (2005) An open letter to our readers on the use of antibodies. The Journal of Comparative Neurology 493, 477-478

9. Gloriam, D. E., Orchard, S., Bertinetti, D., Björling, E., Bongcam-Rudloff, E., Borrebaeck, C. A. K., Bourbeillon, J., Bradbury, A. R. M., de Daruvar, A., Dubel, S., Frank, R., Gibson, T. J., Gold, L., Haslam, N., Herberg, F. W., Hiltke, T., Hoheisel, J. D., Kerrien, S., Koegl, M., Konthur, Z., Korn, B., Landegren, U., Montecchi-Palazzi, L., Palcy, S., Rodriguez, H., Schweinsberg, S., Sievert, V., Stoevesandt, O., Taussig, M. J., Ueffing, M., Uhlén, M., van der Maarel, S., Wingren, C., Woollard, P., Sherman, D. J., and Hermjakob, H. (2010) A Community Standard Format for the Representation of Protein Affinity Reagents. Molecular & Cellular Proteomics 9, 1-10

10. Andreasson, U., Perret-Liaudet, A., van Waalwijk van Doorn, L. J. C., Blennow, K., Chiasserini, D., Engelborghs, S., Fladby, T., Genc, S., Kruse, N., Kuiperij, H. B., Kulic, L., Lewczuk, P., Mollenhauer, B., Mroczyko, B., Parnetti, L., Vanmechelen, E., Verbeeck, M. M., Winblad, B., Zetterberg, H., Koel-Simmelink, M., and Teunissen, C. E. (2015) A Practical Guide to Immunoassay Method Validation. Frontiers in Neurology 6
11. Weller, M. G. (2018) Ten Basic Rules of Antibody Validation. *Anal Chem Insights* 13, 1177390118757462

12. Lund-Johansen, F., and Browning, M. D. (2017) Should we ignore western blots when selecting antibodies for other applications? *Nature Methods* 14, 215

13. Uhlen, M. (2017) Response to: Should we ignore western blots when selecting antibodies for other applications? *Nature Methods* 14, 215

14. Acharya, P., Quinlan, A., and Neumeister, V. (2017) The ABCs of finding a good antibody: How to find a good antibody, validate it, and publish meaningful data. *F1000Research* 6, 851

15. Gilda, J. E., Ghosh, R., Cheah, J. X., West, T. M., Bodine, S. C., and Gomes, A. V. (2015) Western Blotting Inaccuracies with Unverified Antibodies: Need for a Western Blotting Minimal Reporting Standard (WBMRS). *PLOS ONE* 10, e0135392

16. Saper, C. B. (2009) A Guide to the Perplexed on the Specificity of Antibodies. *Journal of Histochemistry and Cytochemistry* 57, 1-5

17. Saper, C. B., and Sawchenko, P. E. (2003) Magic peptides, magic antibodies: Guidelines for appropriate controls for immunohistochemistry. *The Journal of Comparative Neurology* 465, 161-163

18. Bordeaux, J., Welsh, A. W., Agarwal, S., Killiam, E., Baquero, M. T., Hanna, J. A., Anagnostou, V. K., and Rimm, D. L. (2010) Antibody validation. *Biotechniques* 48, 197-209

19. GBSI. (2016) Approaches to Validation. The Science behind Antibody Validation Standards. *GBSI*

20. McDonough, A. A., Veiras, L. C., Minas, J. N., and Ralph, D. L. (2015) Considerations when quantitating protein abundance by immunoblot. *American Journal of Physiology - Cell Physiology* 308, C426-C433

21. Frenzel, A., Hust, M., and Schirrmann, T. (2013) Expression of recombinant antibodies. *Front Immunol* 4, 217-217

22. Smith, K. A., Nelson, P. N., Warren, P., Astley, S. J., Murray, P. G., and Greenman, J. (2004) Demystified...recombinant antibodies. *J Clin Pathol* 57, 912-917

23. Holmseth, S., Zhou, Y., Follin-Arbelet, V. V., Lehre, K. P., Bergles, D. E., and Danbolt, N. C. (2012) Specificity Controls for Immunocytochemistry: The Antigen Preadsorption Test Can Lead to Inaccurate Assessment of Antibody Specificity. *Journal of Histochemistry and Cytochemistry* 60, 174-187
24. GBSI. (2016) Antibody Validation, Standards, Policies, and Practices.

25. Casadevall, A., and Fang, F. C. (2016) Rigorous Science: a How-To Guide. *mBio* 7

26. Casadevall, A., Ellis, L. M., Davies, E. W., McFall-Ngai, M., and Fang, F. C. (2016) A Framework for Improving the Quality of Research in the Biological Sciences. *mBio* 7

27. Greenbaum, D., Colangelo, C., Williams, K., and Gerstein, M. (2003) Comparing protein abundance and mRNA expression levels on a genomic scale. *Genome Biol* 4, 117-117

28. Liu, Y., Beyer, A., and Aebersold, R. (2016) On the Dependency of Cellular Protein Levels on mRNA Abundance. *Cell* 165, 535-550

29. Jo, Y.-I., Suresh, B., Kim, H., and Ramakrishna, S. (2015) CRISPR/Cas9 system as an innovative genetic engineering tool: Enhancements in sequence specificity and delivery methods. *Biochimica et Biophysica Acta (BBA) - Reviews on Cancer* 1856, 234-243

30. Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., and Zhang, F. (2014) Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells. *Science* 343, 84-87

31. Wang, H., Yang, H., Shivalila, C. S., Dawlaty, M. M., Cheng, A. W., Zhang, F., and Jaenisch, R. (2013) One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. *Cell* 153, 910-918

32. Hsu, P. D., Lander, E. S., and Zhang, F. (2014) Development and applications of CRISPR-Cas9 for genome engineering. *Cell* 157, 1262-1278

33. Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., and Charpentier, E. (2012) A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity. *Science* 337, 816-821

34. Olds, W., and Li, J. (2016) siRNA knockdown validation 101: Incorporating negative controls in antibody research. *F1000Research* 5, 308

35. Kiermer, V. (2008) Antibodypedia. *Nature Methods* 5, 860

36. Mackrill, J. J. (2004) Generation, Use, and Validation of Receptor-Selective Antibodies. in *Receptor Signal Transduction Protocols* (Willars, G. B., and Challiss, R. A. J. eds.), Humana Press, Totowa, NJ. pp 47-65

37. Gupta, A., and Devi, L. A. (2006) The use of receptor-specific antibodies to study G-protein-coupled receptors. *The Mount Sinai journal of medicine, New York* 73, 673-681
38. Bodei, S., Arrighi, N., Spano, P., and Sigala, S. (2009) Should we be cautious on the use of commercially available antibodies to dopamine receptors? *Naunyn-Schmiedeberg’s Archives of Pharmacology* 379, 413-415

39. Couchman, J. R. (2009) Commercial Antibodies: The Good, Bad, and Really Ugly. *Journal of Histochemistry and Cytochemistry* 57, 7-8

40. Ivell, R., Teerds, K., and Hoffman, G. E. (2014) Proper Application of Antibodies for Immunohistochemical Detection: Antibody Crimes and How to Prevent Them. *Endocrinology* 155, 676-687

41. Hewitt, S. M., Baskin, D. G., Frevert, C. W., Stahl, W. L., and Rosa-Molinar, E. (2014) Controls for Immunohistochemistry: The Histochemical Society’s Standards of Practice for Validation of Immunohistochemical Assays. *Journal of Histochemistry and Cytochemistry* 62, 693-697

42. Holmseth, S., Dehnes, Y., Bjørsen, L. P., Boulland, J. L., Furness, D. N., Bergles, D., and Danbolt, N. C. (2005) Specificity of antibodies: Unexpected cross-reactivity of antibodies directed against the excitatory amino acid transporter 3 (EAAT3). *Neuroscience* 136, 649-660

43. Geiss, G. K., Bumgarner, R. E., Birditt, B., Dahl, T., Dowidar, N., Dunaway, D. L., Fell, H. P., Ferree, S., George, R. D., Grogan, T., James, J. J., Maysuria, M., Mitton, J. D., Oliveri, P., Osborn, J. L., Peng, T., Ratcliffe, A. L., Webster, P. J., Davidson, E. H., Hood, L., and Dimitrov, K. (2008) Direct multiplexed measurement of gene expression with color-coded probe pairs. *Nature Biotechnology* 26, 317

44. Payton, J. E., Grieselhuber, N. R., Chang, L.-W., Murakami, M., Geiss, G. K., Link, D. C., Nagarajan, R., Watson, M. A., and Ley, T. J. (2009) High throughput digital quantification of mRNA abundance in primary human acute myeloid leukemia samples. *The Journal of Clinical Investigation* 119, 1714-1726

45. Smale, S. T. (2010) Luciferase Assay. *Cold Spring Harbor Protocols* 2010, pdb.prot5421

46. Verhoef, L. G. G. C., Mattioli, M., Ricci, F., Li, Y.-C., and Wade, M. (2016) Multiplex detection of protein–protein interactions using a next generation luciferase reporter. *Biochimica et Biophysica Acta (BBA) - Molecular Cell Research* 1863, 284-292

47. Triglia, T., Thompson, J. K., and Cowman, A. F. (2001) An EBA175 homologue which is transcribed but not translated in erythrocytic stages of *Plasmodium falciparum*. *Molecular and Biochemical Parasitology* 116, 55-63

48. Chu, C. S., Miller, C. A., Gieschen, A., and Fischer, S. M. (2017) Pathway-Informed Discovery and Targeted Proteomic Workflows Using Mass Spectrometry. in *Proteomics: Methods*
and Protocols (Comai, L., Katz, J. E., and Mallick, P. eds.), Springer New York, New York, NY. pp 199-221

49. Liebler, D. C., and Zimmerman, L. J. (2013) Targeted Quantitation of Proteins by Mass Spectrometry. *Biochemistry* 52, 3797-3806

50. Sikorski, K., Mehta, A., Inngjerdingen, M., Thakor, F., Kling, S., Kalina, T., Nyman, T. A., Stensland, M. E., Zhou, W., de Souza, G. A., Holden, L., Stuchly, J., Templin, M., and Lund-Johansen, F. (2018) A high-throughput pipeline for validation of antibodies. *Nature Methods* 15, 909-912

51. Pappin, D. J. C., Hojrup, P., and Bleasby, A. J. (1993) Rapid identification of proteins by peptide-mass fingerprinting. *Current Biology* 3, 327-332

52. Uhlen, M., Bandrowski, A., Carr, S., Edwards, A., Ellenberg, J., Lundberg, E., Rimm, D. L., Rodriguez, H., Hiltke, T., Snyder, M., and Yamamoto, T. (2016) A proposal for validation of antibodies. *Nature Methods* 13, 823

53. Naegle, K., Gough, N. R., and Yaffe, M. B. (2015) Criteria for biological reproducibility: what does "n" mean? *Sci Signal* 8, fs7

54. Signore, M., Manganelli, V., and Hodge, A. (2017) Antibody Validation by Western Blotting. in *Molecular Profiling: Methods and Protocols* (Espina, V. ed.), Springer New York, New York, NY. pp 51-70

55. Willingham, M. C. (1999) Conditional Epitopes: Is Your Antibody Always Specific? *Journal of Histochemistry & Cytochemistry* 47, 1233-1235

56. Ghosh, R., Gilda, J. E., and Gomes, A. V. (2014) The necessity of and strategies for improving confidence in the accuracy of western blots. *Expert review of proteomics* 11, 549-560

57. Kothari, V., and Mathews, S. T. (2015) Detection of Blotted Proteins: Not All Blockers Are Created Equal. *Methods Mol Biol* 1314, 27-32

58. Bass, J. J., Wilkinson, D. J., Rankin, D., Phillips, B. E., Szewczyk, N. J., Smith, K., and Atherton, P. J. (2017) An overview of technical considerations for Western blotting applications to physiological research. *Scandinavian journal of medicine & science in sports* 27, 4-25

59. Mahmood, T., and Yang, P.-C. (2012) Western blot: Technique, theory, and trouble shooting. *North American Journal of Medical Sciences* 4, 429-434

60. Hoffman, W. L., and Jump, A. A. (1989) Inhibition of the streptavidin-biotin interaction by milk. *Analytical Biochemistry* 181, 318-320
61. Ambroz, K. (2011) Impact of Blocking and Detection Chemistries on Antibody Performance for Reverse Phase Protein Arrays. in Protein Microarrays: Methods and Protocols (Korf, U. ed.), Humana Press, Totowa, NJ. pp 13-21

62. Ambroz, K. L. H., Zhang, Y., Schutz-Geschwender, A., and Olive, D. M. (2008) Blocking and detection chemistries affect antibody performance on reverse phase protein arrays. PROTEOMICS 8, 2379-2383

63. DenHollander, N., and Befus, D. (1989) Loss of antigens from immunoblotting membranes. J Immunol Methods 122, 129-135

64. Plant, A. L., Locascio, L. E., May, W. E., and Gallagher, P. D. (2014) Improved reproducibility by assuring confidence in measurements in biomedical research. Nat Methods 11, 895-898

65. Koller, A., and Wätzig, H. (2005) Precision and variance components in quantitative gel electrophoresis. ELECTROPHORESIS 26, 2470-2475

66. Sanders, B. J., Kim, D. C., and Dunn, R. C. (2016) Recent Advances in Microscale Western Blotting. Anal Methods 8, 7002-7013

67. Pan, W., Chen, W., and Jiang, X. (2010) Microfluidic Western Blot. Analytical Chemistry 82, 3974-3976

68. Jin, S., Furtaw, M. D., Chen, H., Lamb, D. T., Ferguson, S. A., Arvin, N. E., Dawod, M., and Kennedy, R. T. (2016) Multiplexed Western Blotting Using Microchip Electrophoresis. Analytical chemistry 88, 6703-6710

69. Zhu, Z., Lu, J. J., and Liu, S. (2012) Protein separation by capillary gel electrophoresis: a review. Anal Chim Acta 709, 21-31

70. Nguyen, U., Squaglia, N., Boge, A., and Fung, P. A. (2011) The Simple Western™: a gel-free, blot-free, hands-free Western blotting reinvention. Nature Methods 8, 982

71. Chow, K. M., Guan, H., and Hersh, L. B. (2010) Aminopeptidases do not directly degrade tau protein. Molecular Neurodegeneration 5, 48

72. Kimple, M. E., Brill, A. L., and Pasker, R. L. (2013) Overview of Affinity Tags for Protein Purification. Current protocols in protein science / editorial board, John E. Coligan ... [et al.] 73, Unit-9.9

73. Shaner, N. C., Steinbach, P. A., and Tsien, R. Y. (2005) A guide to choosing fluorescent proteins. Nat Meth 2, 905-909
74. Snapp, E. (2005) Design and Use of Fluorescent Fusion Proteins in Cell Biology. *Current protocols in cell biology / editorial board, Juan S. Bonifacino ... [et al.] CHAPTER, Unit-21.24*

75. Thirstrup, K., Dächsel, J. C., Oppermann, F. S., Williamson, D. S., Smith, G. P., Fog, K., and Christensen, K. V. (2017) Selective LRRK2 kinase inhibition reduces phosphorylation of endogenous Rab10 and Rab12 in human peripheral mononuclear blood cells. *Scientific Reports 7, 10300*

76. Janes, K. A. (2015) An analysis of critical factors for quantitative immunoblotting. *Science Signaling 8, rs2-rs2*

77. Bakkenist, C. J., Czambel, R. K., Hershberger, P. A., Tawbi, H., Beumer, J. H., and Schmitz, J. C. (2015) A quasi-quantitative dual multiplexed immunoblot method to simultaneously analyze ATM and H2AX Phosphorylation in human peripheral blood mononuclear cells. *Oncosience 2, 542-554*

78. Freedman, L. P., and Inglese, J. (2014) The Increasing Urgency for Standards in Basic Biological Research. *Cancer research 74, 4024-4029*

79. Fosang, A. J., and Colbran, R. J. (2015) Transparency Is the Key to Quality. *Journal of Biological Chemistry 290, 29692-29694*

80. (2017) Announcement: Towards greater reproducibility for life-sciences research in Nature. *Nature 546, 8*

81. (2017) Announcement: Transparency upgrade for Nature journals. *Nature 543, 288*

82. Bandrowski, A. E., and Martone, M. E. (2016) RRIDs: A Simple Step toward Improving Reproducibility through Rigor and Transparency of Experimental Methods. *Neuron 90, 434-436*

83. Collins, F. S., and Tabak, L. A. (2014) Policy: NIH plans to enhance reproducibility. *Nature 505, 612-613*

84. Guilak, F. (2017) New tools for Content Innovation and data sharing: Enhancing reproducibility and rigor in biomechanics research. *J Biomech 54, 1-3*

85. Freedman, L. P., Venugopalan, G., and Wisman, R. (2017) Reproducibility2020: Progress and priorities. *F1000Research 6, 604*

86. Casadevall, A., and Fang, F. C. (2018) Elegant Science. *mBio 9*

87. Edfors, F., Hobær, A., Linderbäck, K., Maddalo, G., Azimi, A., Sivertsson, Å., Tegel, H., Hobær, S., Szigyarto, C. A.-K., Fagerberg, L., von Feilitzen, K., Oksvold, P., Lindskog, C.,
Forsström, B., and Uhlen, M. (2018) Enhanced validation of antibodies for research applications. *Nature Communications* 9, 4130

88. Murano, G. (1997) FDA perspective on specifications for biotechnology products--from IND to PLA. *Developments in biological standardization* 91, 3-13

89. Stirling, A., and Gee, D. (2002) Science, precaution, and practice. *Public Health Reports* 117, 521-533

90. (2013) Guidance for Industry Immunogenicity Assessment for Therapeutic Protein Products

91. Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J., and Klenk, D. C. (1985) Measurement of protein using bicinchoninic acid. *Analytical Biochemistry* 150, 76-85
| Resource | Description | URL |
|----------|-------------|-----|
| Expression Atlas | Open access, gene and protein expression data across species and biological conditions (tissue/cell types, developmental stages, disease, etc.) | www.ebi.ac.uk/gxa/home |
| GeneCards®: The Human Gene Database | A searchable, comprehensive database of annotated/predicted human genes; integrates genomic, transcriptomic, proteomic, genetic, clinical, functional data from many web sources. | www.genecards.org |
| Cancer Cell Line Encyclopedia (CCLE) | A collaborative effort of Broad Institute and Novartis Institutes for Biomedical Research; for genetic and pharmacologic characterization of human cancer models. | https://portals.broadinstitute.org/ccle |
| Human Protein Atlas | Open-source program; maps human proteins in cells, tissues, and organs using integrated omics technologies. | www.proteinatlas.org |
Table 3. Dilution guidelines for unpurified antibody preparations.

Unpurified antibodies will not have a concentration stated on the vendor datasheet. For most whole antiserum, culture supernatant, or ascites fluid products the concentration has not been determined. Unpurified antibody preparations vary significantly in specific antibody concentrations. If the specific antibody concentration of an unpurified antibody preparation is unknown, these concentration estimates may be used as a rough guideline. Please remember that these dilutions and concentration estimates are only a starting point, and dilutions may need to be adjusted based on the experimental results.

| Assay                  | Tissue culture supernatant | Ascites | Whole antiserum | Purified antibody |
|------------------------|----------------------------|---------|-----------------|-------------------|
| Western blot/dot blot  | 1:100                      | 1:1000  | 1:500           | 1 µg/mL           |
| IHC/ICC                | Neat–1:10                  | 1:1000  | 1:50–1:100      | 5 µg/mL           |
| EIA/ELISA              | 1:1000                     | 1:10000 | 1:500           | 0.1 µg/mL         |
| FACS/Flow cytometry    | 1:100                      | 1:1000  | 1:500           | 1 µg/mL           |
| Immunoprecipitation    | N/A                        | 1:100   | 1:50–1:100      | 1–10 µg/mL        |
| Concentration estimate | 1–3 mg/mL                  | 5–10 mg/mL | 1–10 mg/mL | N/A               |
| Antibody Details | Vendor/supplier |
|------------------|-----------------|
|                  | Ab name         |
|                  | Catalog and clone numbers |
|                  | Species of origin |
|                  | Immunogen       |
|                  | Lot or batch number |
|                  | RRID (if available) |
| Validation Strategy | Genetic, orthogonal, and/or other verification |
|                    | Positive and negative controls |
|                    | Antibody titration and optimization |
|                    | Replication |
| Samples | Source (e.g., organism, model, cell type or line) |
|          | Endogenous, purified, tagged, or overexpressed target protein |
|          | Dose, time, activator/inhibitor, or other treatment conditions |
|          | Sample preparation (e.g., lysis conditions, # of cells) |
| Validation Methods | Amount of sample loaded |
|                   | Western blot conditions (including blocking reagent, primary and secondary Ab concentrations, and incubation times) |
|                   | Detection/visualization methods |
Table 5. Suggested benchmarks for user validation of antibody performance in Western blot

| Specificity                                      |
|-------------------------------------------------|
| ✓ Verify by knockdown/knockout of target expression |
| ✓ Appropriate positive and negative controls     |

| Selectivity                                      |
|-------------------------------------------------|
| ✓ Detect target at endogenous levels in a complex sample |
| ✓ Optimize antibody dilutions, assay conditions |

| Reproducibility                                 |
|------------------------------------------------|
| ✓ Repeat/reproduce the experimental result      |
| ✓ Confirm observed effect with a complementary method |
Choose a Commercial Antibody

- Source
- Purity
- Immunogen
- Experimental conditions tested
- Supporting data

Specificity
- Controls
- Genetic verification
- Multiple-epitope approaches
- IP / MS

Selectivity
- Endogenous expression levels
- Antibody dilution and titration
- Blocking buffers

Reproducibility
- Experimental replication
- Biological reproducibility
- Reporting for publication

Figure 1. Key elements of antibody validation.
Figure 2. Effect of blocking buffer on selectivity of an anti-cofilin primary antibody. Cofilin (~19 kDa) was detected on blots blocked with 5% BSA, 5% nonfat dry milk, or Odyssey blocking buffer. Blots were visualized with IRDye 800CW secondary antibody and laser-based digital imaging. All blots were processed identically and imaged together, with blocking buffer as the only variation. Tissue lysates: lane 1, mouse brain; lane 2, rat brain; lane 3, mouse liver; lane 4, rat liver; lane 5, mouse thymus; and lane 6, rat thymus. Arrow indicates the expected position of the 19 kDa cofilin band. Choice of blocking buffer greatly impacted the off-target binding of this antibody. For all primary antibodies tested in this study, BSA consistently produced more non-specific bands than the other blocking buffers. Reprinted with permission from Ambroz et al. *Proteomics* (2008) 8:2379. doi 10.1002/pmic.200700676 ©2008 wiley-vch verlag gmbh & co. kgaa, weinheim
Figure 3. Multiple epitope approach to detect beta catenin in cell lysates and identify potential off-target antibody binding. 20 µg HAP1, A431 and HeLa lysates were loaded into a 4-12% Bis-Tris gel and run under the MOPS buffer system. The membrane was blocked for 1 hour using Odyssey blocking buffer (TBS) before incubation with (A) mouse anti-beta catenin antibody (ab231305) and (B) Rabbit anti-beta catenin antibody (ab35272) and at a 1µg/ml concentration and 1/5000 dilution (0.0000126 µg/ml), respectively. Antibody binding was detected using Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed secondary antibodies at 1/20000 dilution for 1 hour at room temperature. A. ab231305, binding to the C-terminus and visualized in the 700 nm channel (red), displays a strong band at 95 kDa. However, there are several bands at lower molecular weight present in all lysates. B. ab32572, binding the N-terminus of beta catenin and visualized in the 800 nm channel (green), displays a single band at 95 kDa with an additional faint band at 90kDa in A431 lysate, only. C. When both 800 nm and 700 nm channels are displayed both ab32572 and ab231305 show a band at 95 kDa, identifying the full-length beta catenin protein. The additional bands seen for ab231305 are not clearly shown to overlay with ab32572. This could represent off-target binding or isoforms lacking the N-terminal binding domain for ab32572. Membranes were visualized using the Odyssey CLx imager with auto intensity and 84 µm resolution. The membrane was then probed with an anti-GAPDH rabbit antibody conjugated to horseradish peroxidase (HRP)(ab9385). Staining was developed using a GBOX XT-16 chemiluminescent imager with 20 minutes exposure.
Figure 4. Anti-MRP1 antibodies were tested against HAPI wild-type and HAPI ABCC1 knockout (KO) samples in SDS-PAGE. 20 µg of HAPI (WT) and HAPI MRP1 (ABCC1) KO were loaded into a single 3-8% Tris Acetate gels and run under the Tris-Acetate buffer system. The protein gel was transferred onto a single Nitrocellulose membrane. Membrane was blocked in 3% milk (TBS + 0.1% Tween) solution before being spliced into two individual strips (A and B). A. The membrane was incubated with Mouse anti-MRP1 antibody (ab24102) and Rabbit anti-alpha tubulin antibody (ab52866) at a 1/20 dilution and 1/20,000 dilution, respectively. Antibody binding was detected using Goat anti-Mouse IgG H&L (IRDye® 800CW) preadsorbed and Goat anti-Rabbit IgG H&L (IRDye® 680RD) preadsorbed secondary antibodies at 1/20000 dilution. ab24102 clearly displays a single band at 170 kDa in the 800 nm channel (green) that shows reduced signal in the HAPI MRP-1 (ABCC1) knockout lysate. This confirms that ab24102 identifies MRP-1 as well as other off-target proteins. ab52866 staining alpha-tubulin at 50kDa in the 680nm channel (red) confirms equal protein loading across all lanes. B. Membrane was incubated with anti-MRP1 Rabbit antibody (ab233383) and Mouse anti-vinculin antibody (ab130007) at a 1/1000 dilution and 1/20,000 dilution, respectively. Antibody binding was detected using Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed secondary antibodies at 1/20000 dilution. ab233383 displays the expected glycosylated smear for MRP1 between 150-200 kDa in the 800 nm channel (green) that is absent in the HAPI MRP1 (ABCC1) KO lysate. This demonstrates that in HAP1 cells ab233383 reacts only with MRP1 (ABCC1). Ab130007 staining of vinculin at 125 kDa in the 700 nm channel (red) confirms equal protein loading across all lysates. Membranes were visualized using the Odyssey CLx imager with auto intensity and 169 µm resolution. Separate images were required to visualize HiMark™ Pre-stained Protein Standard. White dotted line and scissor symbol denote splicing.
Figure 5. Validation of IDH1 antibody using purified recombinant protein in multi-color and chemiluminescent Western blot. Multi-color Western blots and chemiluminescent Western blots were performed using 10% Bis-Tris SDS PAGE gel and MOPS buffer system, to validate the IDH1 antibody using a purified recombinant IDH1 protein (0.16 µg) containing a c-Myc tag in addition to HEK293T and HeLa whole cell lysates. (A) c-Myc protein tag present on the purified IDH1 recombinant protein is detected in the 700nm channel (red) at 50kDa via mouse anti-c-Myc antibody (ab32; 1 µg/ml) using IRDye 680RD Goat anti-Mouse IgG (H + L) for detection. Some overspill of the recombinant protein into neighboring lanes is observed (white box). (B) IDH1 recombinant protein and endogenous IDH1 protein, present in HEK293T and HeLa, is detected in the 800nm channel (green) at 55kDa and 50kDa respectively using Rabbit anti-IDH1 antibody (ab172964; 1.2 µg/ml) and IRDye 800CW Goat anti-Mouse IgG (H + L) for detection. (C) When both 700nm and 800nm channels are displayed, signal from ab32 and ab172964 overlaps at 50kDa, identifying the c-Myc tagged IDH1 protein. No overlap is seen for the endogenous IDH1 present in HEK293T and HeLa whole cell lysates. (A, B C) Lysate loaded per lane: 20 µg; blocking buffer: Odyssey blocking buffer (TBS); Imager: Odyssey® CLx; resolution: 169 µm; Intensity: auto mode. Chameleon™ Duo pre-stained protein ladder for accurate sizing of protein bands. (D) A single blot was split into two halves (green line) to be incubated with either Rabbit Anti-IDH1 antibody (ab172964; 0.115 μg/ml) or the corresponding rabbit monoclonal IgG isotype control (ab172730; 0.166 μg/ml) in order to detect the endogenous IDH1 protein present in HeLa and HEK293T as well IDH1 recombinant protein. Both halves were incubated with HRP-conjugated Goat anti-Mouse IgG (H + L). (E) A single blot was split into two halves (green line) to be incubated with either Mouse Anti-c-Myc antibody (ab32; 1 µg/ml) and the corresponding mouse monoclonal IgG1 isotype control (ab18443; 1 µg/ml) to detect c-Myc protein tag present on the purified IDH1 recombinant protein but absent in HEK293T and HeLa whole cell lysates. Both halves were incubated with HRP-conjugated Goat anti-Rabbit IgG (H + L). Blots were detected with WesternSure® PREMIUM Chemiluminescent Substrate (LI-COR 926-95000) and imaged on an Odyssey® Fc with resolution: 125 µm and exposure: 2 minutes. Lysate loaded per lane: 20 µg; Protein ladder: WesternSure® Pre-stained Chemiluminescent Protein Ladder (LI-COR 926-980000); blocking buffer: Intercept Blocking Buffer (TBS); Intercept T20 (TBS) Antibody Diluent.
Figure 6. Analysis of phosphorylation specificity using multiplexed Western blot and alkaline phosphatase membrane treatment.

20 µg of LNCaP (lanes 1, 3 and 5) and Jurkat (lanes 2, 4 and 6) whole cell lysates were loaded into a 4-12% Bis-Tris gel and run under the MOPS buffer system. Following transfer, membranes were cut and separated for alkaline phosphatase treatment. Membranes were blocked for an hour using Odyssey Blocking Buffer (TBS) before incubation with rabbit anti-AKT1 (serine473) antibody (ab81283) and mouse anti-AKT1 (ab108202) antibody at a 1/2000 dilution (9.7 µg/ml) and 1/500 dilution (1.67 ug/ml) respectively. Antibody binding was detected using Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed secondary antibodies at 1/20000 dilution. A. In the untreated control membrane ab108202 (red) clearly recognizes a single band at 60 kDa in both lysates that corresponds with the molecular weight of AKT1. ab81283 (green) also detects a single band at 60 kDa corresponding the phosphorylated form of AKT1. Both bands clearly overlap when the channels are merged. B. Membranes treated with the alkaline phosphate reaction buffer displayed identical banding to the control membranes for both AKT1 (ab108202, red) and for pAKT1 (ab81283, green). C. ab108202 (red) displays the expected band at 60kDa for AKT1. No signal is seen for ab81283 (green). Membranes were visualized using the Odyssey CLx imager with auto intensity and 84 µm resolution. Membranes were then probed with an anti-GAPDH rabbit antibody conjugated to horseradish peroxidase (HRP)(ab9385). Staining was developed for 20 minutes using a GBOX XT-16 chemiluminescent imager.
Figure 7. Analysis of PARP1 cleavage by Western blot. HAP1 wild-type and HAP1 PARP1 KO cells with (+) and without (-) staurosporine (STR) treatment were lysed and 20 µg of total protein was loaded into a 4-12% Bis-Tris gel and run under the MOPS buffer system. The membrane was blocked for an hour using Odyssey blocking buffer (TBS) before incubation with rabbit anti-PARP1 antibody (ab32138) and mouse anti-cleaved PARP1 ab110315 at a 1/1000 dilution (9.7 µg/ml) and 1µg/ml concentration respectively. Antibody binding was detected using Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed secondary antibodies at 1/20000 dilution. A. Full length PARP1 was identified at 130 kDa by ab32138 (green) in HAP1 wild-type untreated lysates. Following treatment with staurosporine and cleavage of PARP1 in HAP1 wild-type cells, ab32138 detects a significantly weaker full length PARP1 signal at 130 kDa alongside a new, stronger band at 28 kDa that represents the N-terminal cleavage product. No banding at either molecular weight is seen in treated or control HAP1 PARP1 knockout lysates. B. Following treatment with staurosporine and cleavage of PARP1 in HAP1 wild-type cells, ab110315 (red) identifies the C-terminal cleavage product of PARP1 at 100 kDa. No banding is seen in the untreated wild-type control or in HAP1 PARP1 knockout lysates. C. Overlay of both 800 nm and 70 nm displays clear identification of full length PARP1 and cleavage products in staurosporine treated HAP1 cells. Membranes were visualized using the Odyssey CLx imager with auto intensity and 84 µm resolution. The membrane was then probed with an anti-GAPDH rabbit antibody conjugated to horseradish peroxidase (HRP)(ab9385). Staining was developed for 20 minutes using GBOX XT-16 chemiluminescent imager. D. Illustration of full length PARP1 protein and associated cleavage products. Immunogen domains of ab32138 (green) and ab110315 (red) are displayed with corresponding imaging channel color.
Figure 8. Collaboration and cooperation are required to address the antibody reproducibility problem. Reproducibility requires the combined efforts of the user, vendor, and publisher. Users should perform assay-specific validation of antibody performance and conduct well-designed experiments. Validation results, whether good or bad, can be openly shared and detailed methods reported when the scientific findings are published. The vendor’s role is to provide high quality, well characterized antibodies with detailed disclosure of methods and results. The publisher can formulate and enforce guidelines for antibody validation and data reporting, providing access to detailed methods and other supporting information.Researchers must work together to standardize the way research antibodies are validated, used and reported.
